These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 29792309)

  • 21. Evaluation of poly-mechanistic antiangiogenic combinations to enhance cytotoxic therapy response in pancreatic cancer.
    Awasthi N; Zhang C; Ruan W; Schwarz MA; Schwarz RE
    PLoS One; 2012; 7(6):e38477. PubMed ID: 22723862
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-β1/Gfi-1 axis.
    Xian G; Zhao J; Qin C; Zhang Z; Lin Y; Su Z
    Cancer Lett; 2017 Jan; 385():65-74. PubMed ID: 27840243
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RETSAT associates with DDX39B to promote fork restarting and resistance to gemcitabine based chemotherapy in pancreatic ductal adenocarcinoma.
    Tu Q; Liu X; Yao X; Li R; Liu G; Jiang H; Li K; Chen Q; Huang X; Chang Q; Xu G; Zhu H; Shi P; Zhao B
    J Exp Clin Cancer Res; 2022 Sep; 41(1):274. PubMed ID: 36109793
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular Imaging of the Tumor Microenvironment Reveals the Relationship between Tumor Oxygenation, Glucose Uptake, and Glycolysis in Pancreatic Ductal Adenocarcinoma.
    Yamamoto K; Brender JR; Seki T; Kishimoto S; Oshima N; Choudhuri R; Adler SS; Jagoda EM; Saito K; Devasahayam N; Choyke PL; Mitchell JB; Krishna MC
    Cancer Res; 2020 Jun; 80(11):2087-2093. PubMed ID: 32245793
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Melatonin overcomes gemcitabine resistance in pancreatic ductal adenocarcinoma by abrogating nuclear factor-κB activation.
    Ju HQ; Li H; Tian T; Lu YX; Bai L; Chen LZ; Sheng H; Mo HY; Zeng JB; Deng W; Chiao PJ; Xu RH
    J Pineal Res; 2016 Jan; 60(1):27-38. PubMed ID: 26445000
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NEMO peptide inhibits the growth of pancreatic ductal adenocarcinoma by blocking NF-κB activation.
    Zhuang Z; Li H; Lee H; Aguilar M; Gocho T; Ju H; Iida T; Ling J; Fu J; Wu M; Sun Y; Lu Y; Chiao PJ
    Cancer Lett; 2017 Dec; 411():44-56. PubMed ID: 28951128
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Melittin inhibits tumor growth and decreases resistance to gemcitabine by downregulating cholesterol pathway gene CLU in pancreatic ductal adenocarcinoma.
    Wang X; Xie J; Lu X; Li H; Wen C; Huo Z; Xie J; Shi M; Tang X; Chen H; Peng C; Fang Y; Deng X; Shen B
    Cancer Lett; 2017 Jul; 399():1-9. PubMed ID: 28428074
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lysyl oxidase family activity promotes resistance of pancreatic ductal adenocarcinoma to chemotherapy by limiting the intratumoral anticancer drug distribution.
    Le Calvé B; Griveau A; Vindrieux D; Maréchal R; Wiel C; Svrcek M; Gout J; Azzi L; Payen L; Cros J; de la Fouchardière C; Dubus P; Guitton J; Bartholin L; Bachet JB; Bernard D
    Oncotarget; 2016 May; 7(22):32100-12. PubMed ID: 27050073
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The anti-fibrotic effect of GV1001 combined with gemcitabine on treatment of pancreatic ductal adenocarcinoma.
    Park JK; Kim Y; Kim H; Jeon J; Kim TW; Park JH; Hwnag YI; Lee WJ; Kang JS
    Oncotarget; 2016 Nov; 7(46):75081-75093. PubMed ID: 27655706
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined Src/EGFR Inhibition Targets STAT3 Signaling and Induces Stromal Remodeling to Improve Survival in Pancreatic Cancer.
    Dosch AR; Dai X; Reyzer ML; Mehra S; Srinivasan S; Willobee BA; Kwon D; Kashikar N; Caprioli R; Merchant NB; Nagathihalli NS
    Mol Cancer Res; 2020 Apr; 18(4):623-631. PubMed ID: 31949002
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanisms of metformin's anti‑tumor activity against gemcitabine‑resistant pancreatic adenocarcinoma.
    Suzuki K; Takeuchi O; Suzuki Y; Kitagawa Y
    Int J Oncol; 2019 Feb; 54(2):764-772. PubMed ID: 30570108
    [TBL] [Abstract][Full Text] [Related]  

  • 32. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
    Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X
    Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hypoxia-inducible factor-targeting prodrug TOP3 combined with gemcitabine or TS-1 improves pancreatic cancer survival in an orthotopic model.
    Hoang NT; Kadonosono T; Kuchimaru T; Kizaka-Kondoh S
    Cancer Sci; 2016 Aug; 107(8):1151-8. PubMed ID: 27270607
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma.
    Zhao T; Ren H; Jia L; Chen J; Xin W; Yan F; Li J; Wang X; Gao S; Qian D; Huang C; Hao J
    Oncotarget; 2015 Feb; 6(4):2250-62. PubMed ID: 25544770
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma.
    Borsoi C; Leonard F; Lee Y; Zaid M; Elganainy D; Alexander JF; Kai M; Liu YT; Kang Y; Liu X; Koay EJ; Ferrari M; Godin B; Yokoi K
    Cancer Lett; 2017 Sep; 403():296-304. PubMed ID: 28687352
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Self-Assembled Gemcitabine Prodrug Nanoparticles Show Enhanced Efficacy against Patient-Derived Pancreatic Ductal Adenocarcinoma.
    Wu L; Zhang F; Chen X; Wan J; Wang Y; Li T; Wang H
    ACS Appl Mater Interfaces; 2020 Jan; 12(3):3327-3340. PubMed ID: 31872760
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Myo-inositol trispyrophosphate-mediated hypoxia reversion controls pancreatic cancer in rodents and enhances gemcitabine efficacy.
    Raykov Z; Grekova SP; Bour G; Lehn JM; Giese NA; Nicolau C; Aprahamian M
    Int J Cancer; 2014 Jun; 134(11):2572-82. PubMed ID: 24214898
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models.
    Benito J; Ramirez MS; Millward NZ; Velez J; Harutyunyan KG; Lu H; Shi YX; Matre P; Jacamo R; Ma H; Konoplev S; McQueen T; Volgin A; Protopopova M; Mu H; Lee J; Bhattacharya PK; Marszalek JR; Davis RE; Bankson JA; Cortes JE; Hart CP; Andreeff M; Konopleva M
    Clin Cancer Res; 2016 Apr; 22(7):1687-98. PubMed ID: 26603259
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhancing responsiveness of pancreatic cancer cells to gemcitabine treatment under hypoxia by heme oxygenase-1 inhibition.
    Abdalla MY; Ahmad IM; Rachagani S; Banerjee K; Thompson CM; Maurer HC; Olive KP; Bailey KL; Britigan BE; Kumar S
    Transl Res; 2019 May; 207():56-69. PubMed ID: 30653942
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pancreatic Cancer Chemotherapy Is Potentiated by Induction of Tertiary Lymphoid Structures in Mice.
    Delvecchio FR; Fincham REA; Spear S; Clear A; Roy-Luzarraga M; Balkwill FR; Gribben JG; Bombardieri M; Hodivala-Dilke K; Capasso M; Kocher HM
    Cell Mol Gastroenterol Hepatol; 2021; 12(5):1543-1565. PubMed ID: 34252585
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.